Plus, news about Cipher, ParaPRO, Viracta, ReviR Therapeutics and Luye Pharma:
Collegium’s $525M acquisition: The pain biotech plans to pay that amount, plus a potential $25 million in commercial milestones, for Ironshore Therapeutics, a privately held ADHD drugmaker. — Kyle LaHucik
Syndax’s PDUFA date for leukemia drug is pushed back: The FDA said it needs more time to review additional information provided by Syndax as part of revumenib’s submission, which was filed for relapsed or refractory KMT2Ar acute leukemia. A decision is now expected by Dec. 26, which is three months later than the original deadline. Its stock $SNDX was down about 13% on Monday morning. — Ayisha Sharma
Cipher buys dermatology drugs: The specialty pharma acquired the global product rights to ParaPRO’s lice and scabies topical treatment Natroba and its US commercial sales team for $89.5 million. — Kyle LaHucik
Viracta to lay off 23% of workforce: The Cardiff, CA-based biotech said in an SEC filing that the layoffs will be completed next month. As of March 31, it had 40 full-time employees. The company is in a pivotal Phase 2 for patients with certain forms of EBV-positive peripheral T cell lymphoma. — Kyle LaHucik
ReviR Therapeutics secures $30M in Series A: The Brisbane, CA-based biotech plans to use the funds to “further augment” its AI-powered drug discovery platform, with a focus on finding targets for Huntington’s disease, Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis. The fundraise was led by Lapam Capital, with support from new and existing investors. — Ayisha Sharma
Luye Pharma’s schizophrenia drug wins US approval: The FDA greenlit the company’s extended-release injectable, Erzofri, for schizophrenia and schizoaffective disorder patients as a monotherapy and add-on to mood stabilizers or antidepressants. The atypical antipsychotic drug is administered once a month. — Ayisha Sharma